Charsire is devoted to develop innovative botanic drugs and is one of the few companies which are able to promote the effects of plant extracts over synthetic drugs and biopharmaceuticals. Based on plants, we have developed innovative botanic drugs with multiple functions, which could be used on medical treatment.

CSR

Origin of Charsire

Mr. Yi-Hung Chu, the president of Charsire Biotech Crop, was born in Kaohsiung, and earned his bachelor degree from the department of chemical engineering, National Taiwan University of Science and Technology. However, he switched his research field into traditional Chinese medicine after graduation and devoted himself into it for over 10 years. Mr. Chu tried to discover the effects of every herb on circulations of body and therapeutic effects on different diseases and wounds. After a long exploration and his experience, Mr. Chu found that the herb possess great recoverability and regeneration capacity. Combining the chemical engineering knowledge with Oriental medicine, Mr. Chu expected to bring Traditional Chinese medicine with more scientific future.

 

In 2002, Mr. Yi-Hung Chu established Charsire Biotech Crop. From development of botanic new drugs, skin care products and health care products, Charsire holds the most stringent standard to ensure the efficacy and safety of our products and wish to make people have a healthier and happier life.

 

Founder Mr. Yi-Hung Chu

 

Hopes to shoulder mission of “diligently, persistently, and actively implements the benevolent goodwill of salvation” in order to exert bigger benefit and influence, as well as strive for the health and welfare for all human beings.

Milestone

Since its establishment, Charsire Biotechnology has been met with numerous changes and challenges, though under the collaborative effort of teams from various departments, the company has had a major breakthrough in the field of research and development of new drugs. Charsire emphasizes on innovation and the research and development of various medical pharmacology, while also invests significant efforts and resources in business integrity, corporate governance, environmental protection, energy saving and carbon reduction, social welfare, and labor relations.

2019

Aug

Obtain Medical Device Manufacturer License fromTFDA.

 

The unblinded results for phase II clinical trial of dementia new drug has achieved expected goals and identify potential drug characteristics, as well as the effective populations.

 

Clinical Results of Botanical New Drugs and Topical Health Care Forum.

 

May

 Additional 30 products obtained Halal Certificate (Majelis Ulama Indonesia/MUI)

 

Mar

International certifications of ISO 13485 (Medical Devices)

 

2018

Aug

Acquired Taiwan invention patent.

 

Jun

Acquired Korean invention patent.

 

Apr

10 products obtained Halal Certificate (Majelis Ulama Indonesia/MUI)

Acquired Russia invention patent.

 

2017

Nov

Acquired Australiainvention patent.

 

Aug

Charsire was honored as 2017 Good Business Entity Issuing Uniform Invoices by the National Tax Administration of Southern Taiwan Province.

 

Apr

International certifications of ISO 9001:2015 (Manufacture of Skin Care Products) and ISO 22716 (Manufacture of Skin Care, Cosmetics, Toiletry and Hygiene Products).

 

Apr

The statistical analysis of the clinical results for our new drug relieving the head and neck cancer pain caused by RT, ACA, has been completed. The results showed that most subjects experienced no or mild pain throughout the study duration, and the dermatitis reaction of the radiation area was well-controlled which could be recovered after developing mild dermatitis. This suggested that ACA was able to keep the radiation patients continuously receiving radiation therapy and improve the effect of radiation treatment.

 

Jan

Started patient enrollment in eight investigation centers over U.S. Phase 2 clinical trial investigating BAC in Alzheimer’s Disease or Vascular Dementia treatment.

 

2016

 

Aug

The new drug BAC for Alzheimer’s Disease or Vascular Dementia treatment was approved Phase 2 clinical trial by US FDA.

 

Aug

ACA Phase 1 clinical trial recruitment finished.

 

May

Charsire began the Industry-university cooperative project with National Taiwan Sport University. We expected to establish a new model for the collaboration between sports and industry and supplied our products for the cooperative research.。

 

Jan

Charsire pharmaceutical factory is recognized as PIC/S GMP Pilot Plant Facility.

 

2015

 

Apr

Charsire was ranked in 2015 by Deloitte as one of the 500 fastest growing companies in Asia Pacific.

 

Apr

Charsire Charity Activities: Donate Clothing to Charity.

 

Feb

The new drug ACA for relieving the head and neck cancer pain caused by RT was approved Phase 1 clinical trial by Taiwan FDA.

 

2014

 

Aug

The Phase 2 study for botanical new drug CSTC1 for Diabetic Foot Ulcers was granted by the Ministry of Economic Affairs.

 

Apr

The new drug CSTC1 for Diabetic Foot Ulcer was approved Phase 2 clinical trial by US FDA and Taiwan FDA and was allowed to start enrollment in KMUH, KMSH and KMTH.

 

Apr

 Charsire CSTC1 diabetic wound healing new drug was approved to enter clinical trials.

 

2013

 

Sep

Charsire officially gained approval of public stock offering by Securities and Futures Bureau on 2013/8/26, and came into effect on 2013/9/12. Charsire stock symbols: 4196。 Charsire has been certified as model workplaces in Tainan city.

 

Jul

CSTC1 was approved by FDA  to enter phase II clinical trial.

 

Jun

Obtain the pharmaceutical factory license on 2013/6/7.    Factory Certification : 94-B00105

 

Apr

Officially certificated the patent for medical invention of skin care in Malaysia.

 

Jan

According to banking rules of listed, OTC, and emerging stock companies and FSC, Charsire has started using IFRS financial statements to comply with international practice.

 

2012

 

Nov

Accomplish the research project of diabetes new drug, granted by Industrial Development Bureau.

 

May

Accomplish the research issue, granted by Council of Agriculture, Executive Yuan.

 

Mar

Accomplish the research issue, High value product development of Legume and purple sweet potato, granted by Council of Agriculture, Executive Yuan.

 

Feb

Accomplish the program, CSTC1 diabetes wound healing products of patent extracts, granted by Industrial Development Bureau.

 

2011

 

2011

Honored as the company of phthalate test by Department of Health.

 

2010

 

Dec

Organized and set up Instrumentation Centers, in which contains HPLC, GC/MS/MS, LC/MS/MS, AA…etc.

 

Dec

Introduce the first facial mask with plant extract, which is asepsis and preservative-free.

 

Sep

International certifications of ISO 9001 (Manufacture of Skin Care Products) and 22716 (Manufacture of Skin Care, Cosmetics,Toiletry and Hygiene Products)

 

Jul

Membership marketing of Sfons was established.

 

2009

 

Jun

Sfons Taipei branch office was established.

 

2008

 

Dec

The official opening of Charsire’s factory for R&D/ cosmetics in Tainan Science Park.

 

Aug

The construction of Charsire’s factory in Tainan Science Park was started.

 

Jun

Sfons Kaohsiung branch office was established.

 

Apr

Officially obtained European Patent Convention, including patents of Germany, France, England, Italy, and Netherlands.

 

2007

 

Oct

Officially certificated the second patent for medical invention of skin care in U.S. and  P.O.C.

 

Sep

Invited to Bio Japan 2007 Exhibition.

 

Feb

Officially certificated the patent for medical invention of skin care in E.U. and Singapore. The distribution channel of Sfons Biotech was established.

 

2007

Invited to Bio Japan 2007 Exhibition.

 

2006

 

Sep

Officially certificated the first patent for medical invention in U.S.

 

2005

 

Oct

Invited to Biotechnical 2005 in Hannover, Germany.

 

Jul

 Invited to Bio Taiwan 2005 Conferences & Exhibition.

 

2004

 

Jul

Invited to Bio Taiwan 2004 Conferences & Exhibition.

 

2003

 

Dec

Honor Award of Golden Peak award Outstanding Enterprise Manager Associates, R.O.C. Awarded the National Excellent Quality Product Golden Prize by the Consumers Association.

 

Nov

Nomination of National Biotechnology Medicine Quality Award. Charsire Angastar officially came into the market.

 

Oct

Approval of Ministry of Economics Affairs on capital of 600 million NTD.

 

Aug

Apply for multinational patents in medicine. Patent pending countries: European Union (Britain, France, Germany, Holland, Greece, Italy, Spain , Portugal, Irish, Austria, Belgium,Sweden, Denmark, Finland, Luxembourg, Morocco, Switzerland, Turkey, Bulgaria, Estonia, Czech, Slovakia, Slovenia, Hungary ,Romania, .Liechtenstein, Cyprus), Canada, Australia, Japan, Korea, China, India, Malaysia,Singapore, Taiwan

 

Feb

Officially approved by National Science Council as high biotechnology company of skin medical care and allowed establish and invest cGMP pharmaceutical factory in Tainan Science Park.

+886 6 7020817 | service@charsire.com

 

Copyright © 2019 CHARSIRE BIOTECHNOLOGY CORP, Taiwan R.O.C

 

Unless otherwise specified, all product names appearing in this website are trademarks owned by Charsire Biotechnology Corp. No use of any Charsire trademark, trade name, or trade dress in this site may be made without the prior written authorization of Charsire, except to identify the product or services of the company.